NCT03561181View on ClinicalTrials.gov

Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

PHASE1CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

January 28, 2018

Study Completion Date

February 8, 2018

Conditions
DysenteryDysentery, Bacillary
Interventions
BIOLOGICAL

S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine

Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

BIOLOGICAL

S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine

Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Trial Locations (1)

546300

Yizhou Center for Disease Control and Prevention, Yizhou

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY

NCT03561181 - Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months | Biotech Hunter | Biotech Hunter